IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Source: Newsfilter
Clinical Trial Progress: IO Biotech's pivotal Phase 3 trial for its cancer vaccine Cylembio® is on track, with primary endpoint results expected in Q3 2025. The company aims to submit a Biologics License Application (BLA) to the FDA later this year and plans to launch the vaccine in 2026 if approved.
Financial Performance and Recognition: In Q1 2025, IO Biotech reported a net loss of $22.4 million and was recognized by Fast Company as one of the world's most innovative biotechnology companies, ranking 9th in the sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
